Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
filingDate |
2000-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59e0255e25fefe642c53ca27d8248973 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec0e888de1bb0ed7962a6d99304ab34b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e616e37b2829b3ab67690c8b1b0fa0d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_708bca8b1c92b78ea1ebfbfa935e7eab |
publicationDate |
2003-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2003017143-A1 |
titleOfInvention |
Generation of antigen specific T suppressor cells for treatment of rejection |
abstract |
This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007086965-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10765742-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022240916-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9822161-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9078858-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018228195-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10670603-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009274685-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8299016-B2 |
priorityDate |
1999-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |